Market Intelligence, Clinical Progress, and High-Purity Reagents for MLL-Rearranged Leukemia Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MLLT3/AF9 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MLLT3 (AF9) YEATS Domain (WT) & F59A Mutant Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for assay development. |
View MLLT3 Products |
| Gene Delivery | MLLT3 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and target validation. |
View MLLT3 Products |
| Benchmark Ab | Anti-MLLT3 (AF9) Recombinant Antibody Recombinant positive control for ChIP, Western Blot, and IP assays. |
View MLLT3 Products |
| Validator | MLLT3 siRNA Set For knockdown verification and target specificity assays. |
View MLLT3 Products |
| Related Target A | MLLT1 (ENL) Highly homologous YEATS domain protein. Crucial counter-screening target for selectivity. |
View MLLT1 Products |
| Related Target B | DOT1L Key synergistic histone methyltransferase in the MLL-fusion transcriptional machinery. |
View DOT1L Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against highly homologous MLLT1 (ENL) | Sequence-verified, high-purity (>95%) MLLT3 and MLLT1 YEATS domain proteins available for parallel screening. |
| Epigenetic reader binding assay reproducibility | Endotoxin-controlled, mass spectrometry-verified recombinant proteins preserving native folded states. |
| Lack of negative control for reader assays | Sequence-verified F59A binding-pocket mutant protein available as a precise negative control. |
| False positives in phenotype screening | Validated siRNA sets included for target-specific knockdown verification in cell lines. |
Live MLLT3/AF9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MLLT3/AF9 therapeutics is intensifying, with major players shifting focus from traditional chromatin-associated targets to specialized epigenetic reader domains. As first-generation therapies targeting the MLL-fusion complex (such as Menin-MLL inhibitors) reach advanced clinical phases, the next wave of R&D is targeting the YEATS domain of MLLT3/AF9 to overcome resistance and achieve deeper transcriptional blockade.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (YEATS Inhibitor) | Academic Collaborations, Epigenetic Biopharma | MLL-rearranged Leukemia (AML, ALL) | Selectivity Assay (Need high-purity MLLT3 vs MLLT1 proteins) |
| PROTAC / Degraders | Targeted Protein Degradation Companies | Refractory Hematological Malignancies | Degradation Kinetics (Need Lentivirus for stable reporter cell lines) |
| PPI Inhibitors (AF9-DOT1L) | Oncology-focused Biotech | Pediatric Leukemias | Binding Affinity Assay (Need sequence-verified interaction domains) |